Acasti Pharma Reports Last Patient Visit In TRILOGY 1 Phase 3 Trial Of CaPre For Treatment Of Severe Hypertriglyceridemia, Says On Track To Support Topline Results For TRILOGY 1 In Dec., TRILOGY 2 In Jan. 2020